A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INTERLEUKIN-6 (IL-6) RELATED DISEASES, COMPRISING AN INTERLEUKIN-6 ANTAGONIST (IL-6 ANTAGONIST) AND IMMUNOSUPPRESSANTS. THE IL-6 ANTAGONIST IS PREFERABLY AN ANTIBODY TO AN INTERLEUKIN-6 RECEPTOR (IL-6R).